Kamada Ltd (NASDAQ:KMDA) has received an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Brokerages have set a 12-month consensus target price of $8.50 for the company and are forecasting that the company will post $0.06 EPS for the current quarter, according to Zacks. Zacks has also assigned Kamada an industry rank of 159 out of 265 based on the ratings given to its competitors.
KMDA has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded shares of Kamada from a “sell” rating to a “hold” rating in a report on Wednesday, October 25th. Jefferies Group restated a “buy” rating and issued a $7.00 price target on shares of Kamada in a report on Thursday, October 12th. Finally, ValuEngine upgraded shares of Kamada from a “sell” rating to a “hold” rating in a report on Friday, January 5th.
Shares of Kamada (NASDAQ KMDA) traded down $0.10 during trading on Wednesday, reaching $5.55. 29,700 shares of the company’s stock traded hands, compared to its average volume of 32,420. The company has a current ratio of 3.71, a quick ratio of 2.73 and a debt-to-equity ratio of 0.02. Kamada has a one year low of $3.75 and a one year high of $8.61. The company has a market cap of $227.86, a PE ratio of -138.72 and a beta of 1.03.
Kamada (NASDAQ:KMDA) last issued its earnings results on Monday, November 13th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter. Kamada had a negative return on equity of 1.64% and a negative net margin of 1.27%. research analysts predict that Kamada will post 0.08 earnings per share for the current year.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.